Intracellular boosting of human immunodeficiency virus (HIV) protease inhibitors through inhibition of transport: a novel strategy for potentiating HIV therapy

Royal Liverpool and Broadgreen University Hospitals Trust (UK)0 个研究点目标入组 18 人开始时间: 2008年11月13日最近更新: 2015年1月13日

试验速览

暂无简介。

•1. The ability to understand and sign a written informed consent form, prior to participation in any screening procedures and must be willing to comply with all study requirements
•2. Male or female patients
•3. Aged 18 years and above
•4. HIV positive

•1. History of drug sensitivity or drug allergy to lopinavir, ritonavir, furosemide or dipyridamole
•2. Aged less than 18 years
•3. Pregnant or lactating women
•4. CD4 less than 100 x 10^6 L
•5. Viral load greater than 5000 copies
•6. Anaemia (haemoglobin [Hb] less than 10.0 g/dl)
•7. Severe coronary artery disease
•8. Unstable angina
•9. Recent myocardial infarction or haemodynamic instability
•10. Hypovolaemia or dehydration
•11. Renal dysfunction (estimated glomerular filtration rate [eGFR] less than 70 ml/min/1.73 m^2)
•12. Severe hypokalaemia (K+ less than 3.0 mmol/l)
•13. Severe hyponatraemia (Na+ less than 130 mmol/l)
•14. Men with symptomatic urinary outflow obstruction
•15. Severe hypotension (systolic less than 100 mmHg or diastolic less than 60 mmHg)
•16. Women of childbearing age unless using appropriate contraception
•17. Any known bleeding disorders
•18. International normalised ratio (INR) less than 1.5
•19. Platelets less than 100 x 10^9

发起方

Royal Liverpool and Broadgreen University Hospitals Trust (UK)